DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for juvenile open angle glaucoma — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJuvenile open angle glaucoma maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for juvenile open angle glaucoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 1 subfamily B member 1 (CYP1B1) — CYP1B1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3PM0 · 2.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
Juvenile open-angle glaucoma accounted for 14.7% of paediatric glaucoma cases in a Hong Kong multicentre retrospective analysis of 150 eyes from 98 patients, with a mean presenting age of 5.2 years across all paediatric glaucoma types. In a separate retrospective study of 30 juvenile open-angle glaucoma patients at a tertiary eye centre, the mean age was 26.2 years; 29.97% were aged 20 years or below, and 39.96% had visual acuity of 6/18 or better in the better eye at presentation. The same study reported that 26.64% of patients defaulted within six months, and among the 22 patients who remained on treatment, mean intraocular pressure was 16.35 mmHg. The Hong Kong study found that 63.2% of primary glaucoma eyes and 45.2% of secondary glaucoma eyes were treated surgically, with final mean intraocular pressure of 18.4 mmHg and mean number of glaucoma medications of 2.22 across the entire cohort.
A 2016 trial of latanoprost 0.005% in 35 primary open-angle glaucoma patients aged 55–72 years reported a mean intraocular pressure reduction of 28.6% over three months, with improved optic disc parameters including an 8.4% decrease in cup volume and a 20.8% increase in rim area. That study did not include juvenile patients. The Advanced Glaucoma Intervention Study, reviewing surgically treated open-angle glaucoma, confirmed increased cataract risk after trabeculectomy and identified differential surgical outcomes between black and white patients, but its findings derive from an adult population.
A 2014 review of paediatric glaucoma treatment noted that medications approved for adults carry unknown or more severe risk profiles in children, and that surgical results are associated with significant complications, re-operations, and late failure. A 2021 article on juvenile glaucoma classification and diagnosis emphasises the need for differential diagnostic criteria to distinguish juvenile open-angle glaucoma from congenital glaucoma, but provides no new treatment data. The Hong Kong study reported that 20.7% of paediatric glaucoma presentations were prompted by parental concerns, including cloudy cornea and tearing or photophobia, and that poor visual acuity accounted for 18.0% of presentations.
What remains missing are prospective trials specifically enrolling juvenile open-angle glaucoma patients, data on long-term medication safety and efficacy in this age group, and validated screening protocols that could reduce the advanced-stage presentations documented in the retrospective studies. No drug repurposing evidence for juvenile open-angle glaucoma appears in these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Hong Kong Medical Journal · 2021 · 19 citations · open access
Paediatric glaucoma in Hong Kong: a multicentre retrospective analysis of epidemiology, presentation, clinical interventions, and outcomes
AbstractPURPOSE: To document the epidemiology, presentation, clinical interventions, and outcomes of paediatric glaucoma in Hong Kong. METHODS: This multicentre territory-wide retrospective study was performed by reviewing charts of patients with paediatric glaucoma in six clusters of the Hong Kong Hospital Authority and The Chinese University of Hong Kong from 2006 to 2015. RESULTS: This study included 150 eyes of 98 patients with paediatric glaucoma (presenting age: 5.2±5.7 years). Of them, 35 eyes (23.3%) had primary congenital glaucoma, 22 eyes (14.7%) had juvenile open-angle glaucoma, and 93 eyes (62.0%) had secondary glaucoma. The most prevalent types of secondary glaucoma were lens-related after cataract extraction (18.0%), Axenfeld-Rieger anomaly (5.3%), uveitis (5.3%), Sturge-Weber syndrome (4.7%), and traumatic (3.3%). The most common clinical presentations were parental concerns (20.7%) including cloudy cornea (12.7%) and tearing/photophobia (8.0%), followed by poor visual acuity (18.0%), high intraocular pressure (13.3%), and strabismus (6.0%). The follow-up duration was 8.46±6.51 years. Furthermore, 63.2% of eyes with primary glaucoma and 45.2% of eyes with secondary glaucoma were treated surgically. The final visual acuity was 0.90±0.98 LogMAR; intraocular pressure was 18.4±6.6 mm Hg; and number of glaucoma medications was 2.22±1.61. CONCLUSION: Primary congenital glaucoma was most prevalent, followed by juvenile open-angle glaucoma and aphakic glaucoma. Most eyes with primary glaucoma required surgical treatment. Parental concerns were important clinical presentations. Basic assessments by healthcare providers to identify glaucoma signs (eg, poor visual acuity, high intraocular pressure, and strabismus) warranted prompt referral to an ophthalmologist.
Current Opinion in Ophthalmology · 2003 · 18 citations
Review of recent publications of the Advanced Glaucoma Intervention Study
AbstractPURPOSE OF REVIEW: This review summarizes and evaluates the published reports of the Advanced Glaucoma Intervention Study (AGIS) in the years 2001 and 2002. AGIS evaluated two treatment sequences in medically uncontrolled open-angle glaucoma. Notable initial findings of AGIS included the presence of a race-treatment interaction for the treatment sequences of argon laser trabeculoplasty and trabeculectomy, and that lower intraocular pressures were associated with a reduced progression of visual field damage. RECENT FINDINGS: More recent findings of AGIS include (1). confirmation and quantification of an increased risk of cataract formation following trabeculectomy; (2). identification of risk factors for failure of argon laser trabeculoplasty and trabeculectomy, and the impact of complications on the success of these treatments; and (3). further delineation of a differential response to surgical treatment between black and white patients. SUMMARY: AGIS publications in 2001 and 2002 provide new information regarding the complications and outcomes of surgically treated open-angle glaucoma.
Russian Annals of Ophthalmology · 2016 · 4 citations · open access
Prostaglandin analogues in glaucoma treatment
AbstractAIM: to evaluate the effectiveness of prolatan (latanoprost 0.005%) in the treatment of primary open-angle glaucoma (POAG). MATERIAL AND METHODS: The study included 35 POAG patients (41 eyes) aged 55-72 years, of them 20 men and 15 women. The patients were randomized into two groups followed up for 3 months. Group 1 consisted of 17 patients (19 eyes) who received prolatan once daily in the evening. Group 2 consisted of 18 patients (22 eyes) under Xalatan 0.005% once daily in the evening. RESULTS: The true intraocular pressure (IOP) decreased by the average of 28.6%. Analysis of perimetry results showed a statistically reliable increase in the MD - by 17.4% in the study group and by 20% in the control group, and PSD indices - by 10.7% and 11.9%, respectively. Optical coherence tomography revealed an improvement of optic disc parameters in both groups. In particular, the cup volume decreased reliably by 8.4% and 6.3% and cup area - by 24.4% and 28.5%, respectively, while the rim area increased by 20.8% and 17.9%, respectively. The patients complained of neither burning, nor discomfort, nor foreign body sensation after prolatan instillations. We also report the absence of side effects. CONCLUSION: The study has proved high antihypertensive effectiveness of prolatan. Improved morphometric parameters of the optic disc (decreased cup volume and area, increased rim area) indirectly indicate the neuroprotective potential of the drug. Being well-tolerated by the patients, prolatan can be recommended as the first choice treatment of glaucoma.
Russian Annals of Ophthalmology · 2021 · 3 citations
Classification, diagnosis and treatment of juvenile glaucoma
AbstractJuvenile open-angle glaucoma is a disease with complex pathogenesis affecting young people of working age that can lead to disability. The article describes modern concepts of diagnosis, classification and approaches to the treatment of juvenile glaucoma with special attention paid to the differential diagnostic criteria of juvenile open-angle glaucoma and congenital glaucoma.
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · 2021 · 0 citations
CLINICAL PROFILE AND DEMOGRAPHIC FEATURES OF PATIENTS WITH JUVENILE ONSET OPEN ANGLE GLAUCOMA
AbstractIntroduction- Juvenile open angle glaucoma (JOAG) is a rare form of glaucoma that differs from adult-onset primary open angle glaucoma (POAG) in its age of onset and often in the magnitude of IOP(intraocular pressure) elevation. Objective-To document the demographic characteristics, clinical features and treatment outcome of patients diagnosed with JOAG. Materials And Methods- A non-comparative retrospective study of patients diagnosed with JOAG in the eye clinic of a tertiary eye care centre was done. Data was taken from clinical records and it included the basic demographic features and the clinical characteristics of the patients and the outcome of their treatment. Results- 30 patients were reviewed of which 9 (29.97%) patients were aged 20 years and below. The mean age was 26.2+/- 5.0 years. 12 (39.96 %) had a visual acuity of 6/18 in the better eye at the time of presentation. 8 (26.64%) patients defaulted within six months of presentation. The mean IOPfor the 22 patients who were followed up on treatment, was 16.35+/- 5.0 mmHg. Conclusion- In this study, most patients with JOAG presented an advance form of disease. Early detection through school eye health program and community-based screening would help in reducing the scourge arising from JOAG.
AbstractPediatric glaucoma is a broad term referring to a variety of glaucomas comprising a heterogeneous group of ocular diseases and may occur among individuals from birth to 18 years of age.The paediatric glaucoma presents some of the greatest clinical challenges and can be potentially blinding.At present,medications for adult glaucoma are available to treat pediatric glaucoma,but the risk profiles in children might be more severe than in adults.Surgical results with current techniques are less than outstanding,and are associated with a significant number of complications,re-operations,and late failure.This review summarizes current concepts regarding terminology,classification,epidemiology,medical and surgical treatment,and recent advances with an emphasis on the primary congenital glaucoma,glaucoma following congenital cataract surgery,and glaucoma associated with Sturge-weber syndrome.
Key words:
glaucoma, pediatric/therapy ; medicine ; surgery
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
